Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Neogen Corporation (NASDAQ: ... fiscal year, which ended May 31, increased 19% from ... was $28,158,000, compared to the prior year,s $27,190,000. Adjusted ... earnings per share in the current year were $0.76, ... net income for the 2014 fiscal year established new ...
(Date:7/22/2014)... , Cina, 22 luglio 2014 BGI ... BGI, la maggiore organizzazione di genomica del mondo, ha ... sequenziamento dell,intero esoma umano con base la piattaforma leader ... Genomics, molto apprezzata nel settore per essere in grado ... di precisione e una rilevazione altamente sensibile di tutti ...
(Date:7/22/2014)... and SHENZHEN, China , July ... LTD, (BGI Tech), a subsidiary of BGI, the ... launch of a new human whole exome sequencing ... newly offered service includes in-depth bioinformatics analysis and ... until December 31, 2014. Complete ...
(Date:7/22/2014)... 2014 In chemical and petrochemical ... common sight. The rapid rise of TDL analyzers ... established as a core gas measurement technology, and ... them the gas analyzer technology of choice for ... in some processes have limited their application range. ...
Breaking Biology Technology:Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2
... Target Underlying Defect in Cystic Fibrosis; CFTR ... ... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it ... covering compounds demonstrated to improve cystic,fibrosis transmembrane conductance regulator (CFTR) ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... will begin,immediately. Fentanyl Transdermal System is ... in 25, 50, 75 and 100 mcg/hour ...
... HUNTSVILLE, Ala., Aug. 22 DNA2.0,Inc. ... synthetic genes, and,Operon Biotechnologies (http://www.operon.com ), ... formation of a partnership to utilize their,synergistic ... Operon,s oligonucleotide production platform with DNA2.0,s,gene synthesis ...
Cached Biology Technology:BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 2BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 3BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 4Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2
(Date:7/22/2014)... the survival rates of 12 different shark species ... operations found large differences in survival,rates across the ... hammerhead being the most,vulnerable. The study, led by ... School of,Marine and Atmospheric Science and UM Abess ... to consider for future conservation measures for sharks ...
(Date:7/22/2014)... uncanny precision are key parts of high-powered lenses, ... instead of electricity. But producing these crystals by ... precise beam of electrons, is often extremely difficult ... Columbia universities have proposed a new method that ... specialized materials, known as photonic crystals, with relative ...
(Date:7/22/2014)... hear that drinking milk helps make their bones strong or that ... the idea that if something is good for us, it must ... Journal of Consumer Research , when children hear about the benefits ... predicted that when food is presented to children as making them ... learning how to read or count, they would conclude the food ...
Breaking Biology News(10 mins):New study reveals vulnerability of sharks as collateral damage in commercial fishing 2Technique simplifies the creation of high-tech crystals 2Technique simplifies the creation of high-tech crystals 3
... years ago Mark Kay, MD, PhD, published the first ... RNA interference was an effective gene-therapy technique in mice. ... flurry amongst both academic and industry research groups. , ... way, Kay's initial excitement is proving to be on ...
... phones excite the brain cortex adjacent to it, ... other neurological conditions. This finding is published in ... & Sons. The article is also available online ... million people in the world use cell phones ...
... as Ritalin to quell symptoms of attention deficit hyperactivity ... drugs work in the brain. , But new work ... clear up some of the mystery. Writing in the ... primarily target the prefrontal cortex (PFC), a region of ...
Cached Biology News:For Stanford scientists, RNAi gene therapy takes two steps forward, one step back 2Cell phone emissions excite the brain cortex 2Study reveals how ADHD drugs work in brain 2Study reveals how ADHD drugs work in brain 3
... IgM binds poorly to Protein A and, ... existed for one- step IgM purification. Standard methods ... or they are not effective for removing all ... Pierce has developed ...
... Benzonase is a trademark of Merck KGaA. Physical form: ... pH 8.0, 2 mM MgCl 2 , and 20 ... sonicated herring sperm DNA to acid-soluble oligonucleotides equivalent to ... at pH 8.0 at 37 C (reaction volume 2.625 ...
... NOBLE BSA-Free Stabilizer is a bovine ... It is an aqueous solution ... a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... a combination of 0.02% methylisothiazolone and ...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
Biology Products: